MDxHealth (MDXH) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$114.0M

Revenue (quarter)

$27.2M

Revenue growth (year over year)

+16.31%

Gross profit (trailing twelve months)

$71.7M

Gross margin

62.86%

Net income (trailing twelve months)

−$37.3M

Net income (quarter)

−$11.5M

Net income growth (year over year)

−56.43%

Net margin

−32.74%

Return on equity

—

EPS (trailing twelve months)

−$0.74

Book value per share

−$0.59

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

123.02%

Payout ratio

—

Dividend yield

—

Company profile

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

• Is MDxHealth (MDXH) profitable?

  No. MDxHealth reported a net loss of $37.3M over the trailing twelve months.

• How much revenue does MDxHealth (MDXH) make?

  MDxHealth generated $114.0M in revenue over the trailing twelve months, up 16.31% year over year.

• How do I buy stock in MDxHealth (MDXH)?

  MDXH trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.